Press Releases
AstraZeneca announces positive results from benralizumab phase III programme in severe asthma
AstraZeneca announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase...
News
Mallinckrodt begins patient enrollment in phase 4 study of HP Acthar gel for rare cause of nephrotic syndrome
Mallinckrodt plc a leading global specialty biopharmaceutical company confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy...
Press Releases
Otsuka Holdings Announces Collaboration with ReCor Medical for Commercialization of ReCor Medical’s Ultrasound Renal Denervation Technology in Asia
Otsuka Holdings Co Ltd announced the signing of a development and commercialization agreement with ReCor Medical Inc. together with an additional investment. As part...
Press Releases
Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs
Visionary, up to $2 billion multi-year alliance to focus on development of new gene therapy and gene editing technologies and create a therapeutic...
Research Insight
Allergan Announces Positive Pivotal Trial Results for Oculeve Intranasal Tear Neurostimulator
Allergan plc announced that two pivotal trials of the Oculeve Intranasal Tear Neurostimulator, OCUN-009 and OCUN-010, each met their primary and secondary efficacy endpoints....
Industry Reports
Pfizer To Acquire Anacor
Strong fit with Pfizer’s Inflammation and Immunology portfolio Expected to enhance near-term revenue growth for the innovative business Anacor’s flagship asset, crisaborole, has...
Research Insight
Chugai Pharmaceutical Co Ltd announced Efficacy of Actemra Subcutaneous Injection Confirmed in Dose Interval Reduction Study in Patients with Rheumatoid Arthritis
Chugai Pharmaceutical Co Ltd announced that "Actemra® Subcutaneous Injection" (Actemra), the humanized antihuman IL-6 receptor monoclonal antibody, successfully met the primary endpoint in a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read